CID-103 is a potential best-in-class, clinical stage anti-CD38 monoclonal antibody Safety profile observed in first four dose cohorts supports continued development No serious adverse events or dose-limiting toxicities have been reported SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / September 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative... Read More

SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 3, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will present a company update at the H.C. Wainwright 27 th Annual Global Investment Conference on September 8, 2025 at 10:00 AM... Read More

Industry veteran brings extensive senior level leadership and expertise in biologics development, strategic partnerships, mergers and acquisitions across biotech and large pharma organizations Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb) SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 2, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical... Read More

SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 29, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today reported business and financial results for the quarter ended June 30, 2025 (the "second quarter"). "We are focused on advancing our CID-103 program, a... Read More

SAN FRANCISCO, CA / ACCESS Newswire / August 28, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will participate in a fireside chat at the Cantor Global Healthcare Conference on Wednesday, September 3 at 11:30 AM ET in New York... Read More

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitope Phase 1 study in adults with active and chronic active renal allograft AMR planned to initiate AMR is a leading cause of kidney transplant loss, leading to dialysis and/or repeat renal transplant SAN FRANCISCO, CA / ACCESS Newswire / August 4, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical... Read More

David Cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record of building and leading high performing operating teams and financing in the capital markets with over $1B+ raised and multiple company exits by acquisition CID-103 is a potential best in class, anti-CD38 monoclonal antibody,... Read More

BEIJING, CHINA / ACCESS Newswire / May 19, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that it will host a live conference call and webcast at 8:00 a.m. PT/11:00 a.m. ET on Wednesday, May 21, 2025 to provide business and clinical update. A... Read More

BEIJING, CN / ACCESS Newswire / May 16, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the quarter ended March 31, 2025. Dr. Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, "We... Read More

BEIJING, CHINA / ACCESS Newswire / May 12, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has entered into a definitive Equity and Assets Transfer Agreement (the "Equity and Assets Transfer Agreement") with Kaixin Pharmaceuticals... Read More

BEIJING, CHINA / ACCESS Newswire / May 7, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") dated May 5, 2025 stating that the Company is not in... Read More

BEIJING, CN / ACCESS Newswire / April 3, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI, "CASI"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that its special committee of the board of directors (the "Special Committee") has received an updated preliminary non-binding proposal letter (the "Proposal Letter"), dated... Read More

BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the fourth quarter ended December 31, 2024, and provided an update on key highlights for 2024. Wei-Wu He, Ph.D.,... Read More

BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended September 30, 2024. Dr. Wei-Wu He, Chairman and CEO of CASI, said "The... Read More

BEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) to proceed with a phase 1/2... Read More

BEIJING , Sept. 4, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today announced its participation in the H.C. Wainwright 26 th Annual Global Investment Conference taking place September 9-11, 2024 , at the Lotte New York... Read More

BEIJING , Aug. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended June 30, 2024 . "The second quarter of 2024 was a period of significant progress... Read More

BEIJING , July 19, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. For details, please visit below link: Click Here About CASI... Read More

BEIJING , July 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang , MD as Chief Financial Officer and Senior Vice President, effective July 8 th , 2024. Dr. Lang has more than 30 years of experience as a physician scientist,... Read More

BEIJING , June 26, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, announced today that the Company is planning to submit an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA") for CID-103 for the treatment... Read More

BEIJING , June 26, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, announced today that it has entered into securities purchase agreements with certain investors for a private investment in public equity financing (the "PIPE Transaction") that is... Read More

BEIJING , May 15, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced today the following: On April 12, 2024 CASI submitted the IND application to the FDA for CID-103 to support a phase 1/2 study of CID-103 in adults with chronic Immune Thrombocytopenia (ITP). On May... Read More

BEIJING , May 14, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the three months ended March 31, 2024 . In the first quarter of 2024, CASI's total revenue was $3.4 million . Total revenue decreased by 59% compared to the same... Read More

BEIJING , April 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. For details, please click here . About CASI Pharmaceuticals CASI... Read More

BEIJING , March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023 , and provided an update on key highlights for 2023. CASI reported fourth quarter 2023 revenue of $6.9 million for... Read More

BEIJING and LUND, Sweden , March 5, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for... Read More

BEIJING , Feb. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, proudly announced the administration of the first dose of FOLOTYN ® (Pralatrexate Injection) to a patient in China . This remarks a pivotal step in CASI's commitment to addressing critical medical needs in... Read More

BEIJING , Nov. 14, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the third quarter ended September 30 , 2023 Dr. Wei-Wu He , Chairman and CEO of CASI Pharmaceuticals, stated, "We are delighted to announce that our partner Juventas has... Read More

BEIJING , Nov. 8, 2023 /PRNewswire/ -- CASI Pharmaceuticals Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, is thrilled to announce a major milestone in its partnership with Juventas Cell Therapy Ltd. (Juventas). The China National Medical Products Administration (NMPA) has granted market approval for Juventas' investigational... Read More

BEIJING , Aug. 11, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. ( Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the quarter ended June 30 , 2023. Wei-Wu He , Ph.D., CASI's Chairman and Chief Executive Officer, commented, "We are pleased to report $9.8 million sales revenue for the second quarter... Read More

BEIJING , Aug. 1, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of an Assignment Agreement (the "Agreement") with Mundipharma International Corporation Limited ("MICL"), Mundipharma Medical Company ("MMCo"), and Acrotech Biopharma Inc. ("Acrotech") for the... Read More

BEIJING , July 20, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of the Assignment Agreement (the "Agreement") with Cleave Therapeutics, Inc. ("Cleave"), pursuant to which CASI obtained all rights and global intellectual property rights related to CB-5339,... Read More

BEIJING , May 17, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the three months ended March 31, 2023 . Wei-Wu He , Ph.D., CASI's Chairman and Chief Executive Officer, commented, "Revenue for EVOMELA ® was $8.3 million in... Read More

BEIJING , April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022 , with the U.S. Securities and Exchange Commission ("SEC") on April 26, 2023 . The annual... Read More

BEIJING , April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2022 , and provided an update on key highlights for 2022. Wei-Wu He , Ph.D., CASI's Chairman and Chief Executive Officer, commented, "We... Read More

BEIJING , March 21, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that the redomiciliation merger to redomicile the Company as a Cayman Islands company (the "Redomiciliation Merger") has been completed. Pursuant to the Redomiciliation Merger,... Read More

NMPA approved CB-5339 CTA for Multiple Myeloma indication Expected enrollment to begin in 2023 ROCKVILLE, Md. and BEIJING , Jan. 6, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces that the China National Medical Products Administration (NMPA) has approved the Company's... Read More

ROCKVILLE, Md. and BEIJING , Dec. 15, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that China National Medical Products Administration (NMPA) has accepted the new drug application (NDA) from Juventas Cell Therapy, Ltd., (Juventas) for CNCT19 (Inaticabtagene... Read More